PRME Insider Trading Activity and SEC Form 4 Filings
PRME insider trading summary
No open-market insider purchases or sales of Prime Medicine, Inc. (PRME) have been reported on SEC Form 4 in the past 12 months.
Latest PRME insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 1, 2025 | Robert Nelsen | Director | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | Steven Gillis | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | Keith Crandell | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | Kristina Burow | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | ARCH Venture Partners X, L.P. | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | ARCH Venture Partners X, LLC | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | ARCH Venture Fund X, L.P. | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | ARCH Venture Partners X Overage, L.P. | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | ARCH Venture Fund X Overage, L.P. | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
| Aug 1, 2025 | ARCH Venture Fund XII, L.P. | 10% Owner | Buy | $10.0M (3,030,300 @ $3.30) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.